NCT01396512View on ClinicalTrials.gov

Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers

PHASE3CompletedINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

June 30, 2013

Conditions
Japanese EncephalitisJapanese Encephalitis Virus Disease
Interventions
BIOLOGICAL

Live attenuated Japanese encephalitis chimeric virus vaccine

0.5 mL, Subcutaneous

BIOLOGICAL

Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)

0.5 mL, Subcutaneous

Trial Locations (6)

Unknown

Goyang

Incheon

Seongnam

Seoul

Suwon

Wŏnju

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01396512 - Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers | Biotech Hunter | Biotech Hunter